Preregistration
Esketamine for Treatment of Cognitive Decline in Alzheimer’s Disease: Systematic Review of Pre-clinical and Clinical Studies
Abstract
A systematic review of preclinical and clinical evidence that esketamine may hold potential to alleviate cognitive decline associated with Alzheimer’s disease and the possible mechanistic pathways.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Keywords
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
Related research
ArticleMDMA
Chemsex drugs: More than ghb, mephedrone and methamphetamine?
ArticleKetamine
Midazolam-Ketamine (MK) Versus Propofol-Ketamine (PK) for Pediatric Burn Patients Undergoing Dressing Changes: A Non-Randomized Cross-Over Clinical Trial.
ArticleKetamine